Novartis | NVS - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 645M 69M 2026-03
Amgen USD 657M 4M 2026-03
AstraZeneca USD 484M 181M 2025-12
Bausch Health Companies USD 397M 15M 2025-12
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 411M 21M 2026-03
Canopy Growth CAD 12.31M 4.97M 2026-03
Corcept Therapeutics USD 814.88M 809.46M 2026-03
Drreddys Laboratories INR 1.06B 113M 2026-03
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 240M 15M 2026-03
GlaxoSmithKline GBP 167M 21M 2026-03
Glaxosmithkline GBP 192.73M 14.79M 2026-03
J&J USD 43M 25M 2026-03
Merck USD 479M 67M 2026-03
Novartis USD 343M 39M 2026-03
Novartis USD 281M 8M 2025-09
Pacira USD 3.7M 193K 2026-03
Perrigo USD 7.98B 7.94B 2026-03
Pfizer USD 671M 40M 2026-03
Phibro Animal Health USD 11.91M 191K 2025-12
Prestige Brands USD 10.67M 636K 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sanofi EUR 178M 203M 2026-03
Sanofi EUR -25M 99.78M 2025-12
Supernus Pharmaceuticals USD 910K 278K 2023-06
Zoetis USD 62M 5M 2026-03